CClinicalTrials.gg
TerminatedNCT03138434Updated Jul 5, 2019

Advanced MRI in AAA

An observational study in Abdominal Aortic Aneurysm, sponsored by Ron Balm. Terminated at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-05.

Sponsored by Ron Balm · Observational

Why this study was terminated
Sufficient acquisitions for DCE-MRI and 4D flow, but not for T1/T2-mapping due to lack of ILT in some participants.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
31
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to determine whether advanced MRI sequences can provide robust and clinically relevant information about abdominal aortic aneurysms (AAAs). The MRI sequences will study outcomes related to blood flow inside AAA, microvasculature of the AAA vessel wall and intraluminal thrombus inside AAA.

Robustness of these MRI sequences will be determined with testing of feasibility and reproducibility. Clinical relevance will be assessed by studying the association between the primary outcomes and disease severity. Disease severity will be expressed by AAA diameter.

It is our hypothesis that these parameters are significantly related to disease severity and may therefore be future markers of disease progression.

Read the detailed description

This prospective study evaluates the feasibility, reproducibility and clinical relevance of MRI sequences in adults with an abdominal aortic aneurysm (AAA).

The MRI sequences and their primary outcomes are:

  • Four-dimensional (4D) flow MRI and wall shear stress (WSS)
  • Dynamic Contrast-Enhanced (DCE) MRI and kinetic transport constant (Ktrans)
  • T1 and T2 mapping (T1 and T2 relaxation times)

Feasibility is tested by the production of high-quality images that enable calculation of the primary outcomes. Reproducibility is tested by calculating interscan, intra- and interobserver variability. Clinical relevance is tested by assessing the association between primary outcomes and disease severity which is expressed by AAA diameter

02

Conditions studied

  • Abdominal Aortic Aneurysm

Keywords

  • Abdominal Aortic Aneurysm
  • 4D flow MRI
  • DCE-MRI
  • T1 and T2 mapping
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients with an abdominal aortic aneurysms who are patients at the department of vascular surgery of the Academic Medical Center.

Inclusion criteria

  • Adult patients (≥ 18 years of age)
  • Abdominal aortic aneurysm with a maximal aneurysm diameter of at least 30 mm

Exclusion criteria

Exclusion Criteria:

  • Contra-indications for MRI
  • Severely reduced renal function (eGFR \< 30)
  • Previous allergic reaction to intravenous contrast agents
  • Suprarenal AAA
  • Pararenal AAA
  • Previous aneurysm repair
  • Inflammatory aneurysm
  • Mycotic or other infectious aneurysm
  • Vasculitis
  • Connective tissue disease
04

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
31 participants (actual)
Patient registry
No

Groups and cohorts

  • Optimization phase

    The first five patients will be included for the optimization of the MRI sequences. This is to ensure that a standard protocol will work for different sizes of AAA. These patients will only be scanned once.

  • Study phase

    This phase will commence after the optimization phase. This phase is where we want to assess the feasibility, reproducibility and association with disease severity between MRI parameters and AAA. These twenty patients will be scanned twice, with an interval of 1 week ± 5 days. The study will be completed when we have 20 patients with 2 scans for each sequence, or when a maximum number of 30 patients in the study phase have been scanned.

05

What researchers measure

Primary outcomes

  1. Wall shear stress (WSS)

    Primary outcome of 4D flow MRI

    Time frame: Time of MRI scan

  2. Kinetic transport constant (Ktrans)

    Primary outcome of DCE-MRI

    Time frame: Time of MRI scan

  3. T1 relaxation time

    Primary outcome of T1 mapping

    Time frame: Time of MRI scan

  4. T2 relaxation time

    Primary outcome of T2 mapping

    Time frame: Time of MRI scan

Secondary outcomes

  1. Peak flow velocity inside the aneurysm

    Secondary outcome of 4D flow MRI

    Time frame: Time of MRI scan

  2. Location of peak wall shear stress

    Secondary outcome of 4D flow MRI

    Time frame: Time of MRI scan

  3. Flow velocity at aneurysm entrance

    Secondary outcome of 4D flow MRI

    Time frame: Time of MRI scan

  4. Flow patterns

    Secondary outcome of 4D flow MRI

    Time frame: Time of MRI scan

  5. Oscillatory shear index

    Secondary outcome of 4D flow MRI

    Time frame: Time of MRI scan

  6. Reverse reflux rate constant (kep)

    Secondary outcome of DCE-MRI

    Time frame: Time of MRI scan

  7. Area under the curve of contrast uptake

    Secondary outcome of DCE-MRI

    Time frame: Time of MRI scan

  8. Peak enhancement ratio

    Secondary outcome of DCE-MRI

    Time frame: Time of MRI scan

  9. Wash-in slope

    Secondary outcome of DCE-MRI

    Time frame: Time of MRI scan

  10. Time to peak (TTP)

    Secondary outcome of DCE-MRI

    Time frame: Time of MRI scan

  11. Mean transit time (MTT)

    Secondary outcome of DCE-MRI

    Time frame: Time of MRI scan

06

Study locations

1 site
  • Department of Vascular Surgery
    Amsterdam, Netherlands
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03138434
Lead sponsor
Ron Balm
Responsible party
Ron Balm (prof. dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Sponsor-investigator
First posted
May 3, 2017
Start date
Apr 12, 2017
Primary completion
May 29, 2019
Completion
May 29, 2019
Last update
Jul 5, 2019

Study contacts

Ron Balm, MD PhD
principal investigator · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion